RecruitingNCT02917369
Integrative Analysis of Large-cell Lung Cancer
Integrative Analysis of Large-cell Lung Carcinoma
Sponsor
Shanghai 10th People's Hospital
Enrollment
1,000 participants
Start Date
Jan 1, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
Integrative analysis of LCLC
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria4
- Age ≤ 75 years with histologically proven LCLC
- No severe major organ dysfunction
- World Health Organization (WHO) performance status of 0 or 1
- No prior cancer chemotherapy
Exclusion Criteria4
- Age ≥ 76
- Severe major organ dysfunction
- WHO performance status of \>1
- Prior cancer chemotherapy
Interventions
OTHERNormal lung tissue
The investigators will extract total protein, DNA and RNA from LCLC patients.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02917369
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
Rhomboid Intercostal Block vs Erector Spinae Block
NCT070406181 location
Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
NCT062954971 location
Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block
NCT066185991 location